Beaumont Hospital

Running trials

• Recruiting

  A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  NCT07218341· Phase 4· Source

• Recruiting

  A Pivotal Study Evaluating Safety and Effectiveness of Adaptative Tip Catheter in Patients With Acute Ischemic Stroke

  NCT07367100· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  NCT06793215· Phase 3· Source

• Recruiting

  Measurement and Impact of Physical Impairment in Amyotrophic Lateral Sclerosis: Use of Digital Technologies - A Precision ALS Project

  NCT06820008· Source

• Active, not recruiting

  U011 - Wireless Ultra Long-Term EEG Recordings in Epilepsy

  NCT05915988· Source

• Active, not recruiting

  Prospective Observational Study of Effectiveness and Safety of Filgotinib in Participants With Ulcerative Colitis (UC)

  NCT05817942· Source

• Recruiting

  Precision Diagnosis and Care for Families With Pulmonary Fibrosis in Ireland

  NCT06702228· Source

• Active, not recruiting

  Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

  NCT04704934· Phase 3· Source

• Active, not recruiting

  Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

  NCT04595565· Phase 3· Source

• Active, not recruiting

  A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT04033445· Phase 2/3· Source

• Active, not recruiting

  A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis

  NCT03523858· Phase 3· Source

• Active, not recruiting

  Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma

  NCT02811861· Phase 3· Source

• Recruiting

  Breast Cancer Proteomics and Molecular Heterogeneity

  NCT01840293· Source

• Active, not recruiting

  Prostate Advances in Comparative Evidence

  NCT01584258· Phase 3· Source

• Recruiting

  Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort

  NCT01574053· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• ALS (motor neurone disease)1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Huntington's disease1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• Lung cancer1 recruiting
• Metastatic breast cancer1 recruiting
• Stroke1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Recruiting

  A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

  NCT06091865· Phase 3· Source

• Completed

  Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis

  NCT02914535· Phase 3· Source

• Completed

  Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation

  NCT02950051· Phase 3· Source

• Completed

  Colchicine for Prevention of Vascular Inflammation in Non-cardio Embolic Stroke

  NCT02898610· Phase 3· Source

• Completed

  Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1

  NCT02620280· Phase 3· Source

• Completed

  A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion

  NCT02398656· Phase 3· Source

• Completed

  A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)

  NCT01740427· Phase 3· Source

• Completed

  Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery

  NCT00324805· Phase 3· Source